We previously reported that 17-b-estradiol (E2)-induced mitochondrial reactive oxygen species (mtROS) act as signaling molecules. The purpose of this study was to investigate the effects of E2-induced mtROS on cell cycle progression. E2-induced cell growth was reduced by antioxidants N-acetyl-L-cysteine (NAC), catalase, and the glutathione peroxidase mimic ebselen. Flow cytometry showed that mitochondrial blockers of protein synthesis (chloramphenicol), transcription and replication (ethidium bromide), and function (rotenone, rhodamine 6G) blocked E2-induced G 1 to S transition. Reduction of E2-induced DNA synthesis in the presence of mitochondrial blockers occurred without influencing the level of ATP. Additionally, the mitochondrial blockers inhibited the E2-induced expression of early cell cycle genes such as cyclins D1, D3, E1, E2, and B2. NAC or rotenone reduced E2-induced cyclin D1 expression. Furthermore, E2-induced binding of AP-1 and CREB to the TRE and CRE response sequences, respectively, in the promoter of cyclin D1 was inhibited by NAC or rotenone. In addition, E2-induced expression of PCNA, PRC1, and bcl-2 were inhibited by mitochondrial blockers. These data indicate that E2-induced mtROS are involved in the regulation of early G 1 -phase progression. Since neither antioxidants nor mitochondrial blockers used in this study are reported to bind the estrogen receptor (ER), our findings suggest that E2-induced mtROS modulates G 1 to S transition and some of the early G 1 genes through a nongenomic, ERindependent signaling pathway. Thus, our results suggest (1) a new paradigm that estrogen-induced mitochondrial oxidants control the early stage of cell cycle progression and (2) provide the basis for the discovery of novel antioxidant-based drugs or antioxidant gene therapies for the prevention and treatment of estrogen-dependent breast cancer.
Introduction
There is considerable evidence, both experimental and epidemiologic, that estrogens play a role in breast carcinogenesis (IARC working group, 1999; DuMond Jr et al., 2001a, b; National Toxicology Program, 2002) . Estrogens elicit different growth responses in tissues depending on the cell type, and dose and timing of exposure (Roy and Cai, 2002) . It is now widely accepted that estrogen plays a role in the promotion of breast tumors and estrogen is considered to support the growth of preneoplastic and malignant cells through estrogen receptor (ER)-mediated signaling pathways (Roy and Singh, 2004) . The conventional paradigm of estrogen action is based on binding to its receptors, ERa/b, which initiates transcription either directly by binding to estrogen response elements (EREs) of genes or indirectly through the phosphorylation of signaling proteins involved in cell cycle progression. Discrepancies between the binding affinity of various estrogens to the ER and their growth potency both in vitro and in vivo have been reported (Bocchinfuso et al., 1999; DuMond Jr et al., 2001a, b) . Although selective ER modulators (SERMS) such as tamoxifen and antiestrogens such as ICI 182 780 prevent the growth of cancer, the contribution of other mechanisms cannot be ruled out as these compounds also block metabolism and redox cycling of estrogen, and are free radical scavengers (Arteaga et al., 2003) .
Cyclin D1 is a growth regulatory gene activated by 17-b-estradiol (E2) in MCF7 cells, and in rodent breast epithelial tissue, ovary, and uterine endometrium; and is not reported to contain an ERE-related sequence in its proximal promoter (Sicinski et al., 1995; Sabbah et al., 1999; Foster et al., 2001) . The addition of E2 to G 0 /G 1 -arrested MCF7 cells results in a 2-3-fold induction of cyclin D1 mRNA within 1-3 h and a 3-5-fold increase in protein synthesis and steady-state levels of cyclin D1 within 3-6 h (Foster et al., 2001) . Given that cyclin D1 knockout mice are fertile, the physiologic relevance of cyclin D1 as a direct target of ER actions is not certain. E2 has been demonstrated to upregulate transiently the synthesis of c-fos and c-jun in MCF7 cells but not in hER-transfected HaCaT-nontransformed human keratinocytes (Planas-Silva et al., 1999) . Additionally, earlier studies have demonstrated that E2 increased AP-1 activity without increased synthesis of c-jun or c-fos and without the synthesis of any new proteins. Together, these findings suggest that the activation of AP-1, a critical regulator of E2-induced cell growth, does not depend entirely on ER-mediated actions. The products of at least two E2 target genes, c-myc and cyclin D1, can independently promote G 1 /S transition in MCF7 cells (Foster et al., 2001) . However, an unresolved issue regarding E2-mediated signaling is whether ERs themselves actually initiate the early signal responsible for G 1 /S transitions. Based on the above findings, it appears that in addition to ER-mediated genomic signaling pathways, a non-ER pathway(s) is also involved in supporting the estrogen-dependent early growth of preneoplastic and neoplastic cells.
The expression of early G 1 genes: c-myc, c-fos, c-jun, and cyclin D1 are regulated by reactive oxygen species (ROS) (Janssen et al., 1997; Simon et al., 1998; Galli et al., 2003) . Low and intermediate levels of ROS regulate cellular signaling and play an important role in normal cell proliferation (Sauer et al., 2001) . The rapid stimulation of intracellular ROS by platelet-derived growth factor, epidermal growth factor, and nerve growth factor (Droge, 2002) suggests that this underlying mechanism of cell growth may be shared with other growth-supporting agents including estrogen. Recently, we and others have reported that mitochondria are significant targets of estrogen (Chen and Yager, 2004; Chen et al., 2004a, b; Felty and Roy 2005a, b) . Therefore, we have examined whether E2-induced ROS control the early signal for the growth of breast cancer cells. We investigated the influence of antioxidants, as well as blockers of mitochondrial protein synthesis, transcription, and oxidative phosphorylation on estrogen-induced cell growth, G 1 /S phase transitions, and the expression of cell cycle genes.
Results
Antioxidants and mitochondrial blockers reduce E2-induced cell growth. Growth factors are known to stimulate a rapid increase of intracellular ROS that participate in cell signaling pathways involved in growth. Recently, we have shown that physiological concentrations of E2 result in the rapid production of ROS in epithelial cells (Q Felty et al., unpublished) ; however, the biological role of these oxidants in the control of E2-induced cell growth is not clear. Therefore, we evaluated the effect that antioxidants had on E2-induced growth of epithelial cells. As shown in Figure 1a , N-acetyl-L-cysteine (NAC) reduced E2-induced cell growth to the level of the control, while the antioxidant enzyme catalase significantly inhibited E2-induced cell growth by as much as 50% after a 72 h treatment. The reduction of E2-induced cell growth observed with NAC and catalase treatment was confirmed by the sulforhodamine B (SRB) assay (Figure 1b) . The SRB assay also demonstrated that the glutathione peroxidase mimic, ebselen, effectively reduced E2-induced cell growth to the level of the control. These findings indirectly demonstrate that E2-induced oxidants support the growth of epithelial cells.
Recently, we have shown that mitochondria are a major source of E2-induced ROS in breast cancer cells. To evaluate whether E2-induced mitochondrial ROS (mtROS) signal the growth of breast cancer cells, we tested the effect of mitochondrial blockers on E2-induced cell growth. Several different approaches were used to test whether E2-induced mtROS signaled cell growth. First, we cultured MCF7 for 4 days with chloramphenicol or doxycycline in order to block mitochondrial protein synthesis prior to the start of cell growth experiments. The rationale for the use of mitochondrial protein synthesis blockers is based on the fact that the electron transport chain generates a substantial amount of intracellular ROS (Shigenaga et al., 1994 ). Since we have already shown that chloramphenicol treatment reduced E2-induced ROS in MCF7 cells (Q Felty et al., unpublished) , we made the assumption that mtROS production would be impaired by a deficiency of mitochondrial proteins necessary for the proper function of the electron transport chain. As shown in Figure 1c , both blockers of mitochondrial protein synthesis reduced E2-induced breast cancer cell growth. Chloramphenicol reduced E2-induced cell growth to the control level, while doxycycline treatment resulted in a 50% reduction in growth. Studies of the mitochondrial electron transport chain have reported only two ROS-forming sites: the FMN group of complex I and the ubiquinone site in complex III (Turrens et al., 1985; Liu et al., 2002) . Therefore, we used specific chemical blockers of mitochondrial respiratory complex I (rotenone) and III (antimycin A). Rotenone significantly reduced E2-induced cell growth to the control level and a similar effect was also observed with antimycin A (Figure 1c ). The reduction of E2-induced cell growth observed with rotenone and antimycin A treatments was confirmed by the SRB assay ( Figure 1d ). Together, these findings suggest that E2-induced growth of epithelial cells depends on ROS of mitochondrial origin.
Antioxidants and mitochondrial blockers suppress E2-induced DNA synthesis
In order to confirm the previous data on the effect of antioxidants on cell proliferation, we tested the influence of antioxidants on E2-induced DNA synthesis. E2-induced DNA synthesis, as evaluated by BrdUrd incorporation, was significantly decreased 50% by both ebselen and NAC treatments at 18 h (Figure 2a ). This was also the case for the antioxidant enzyme catalase. Since mitochondria are a major source of E2-induced ROS in breast cancer cells, we used several different approaches to test whether mtROS play a role in E2-induced DNA synthesis.
MCF7 cells were treated with ethidium bromide (EtBr) (50 ng/ml), which is known to block mitochondrial transcription/replication in breast cancer cells (Delsite et al., 2002) . Since EtBr intercalates the mtDNA, new mtDNA replication, transcription, and protein synthesis are effectively halted, which results in an incomplete mitochondrial respiratory chain. The rationale for blocking new mitochondrial transcription/replication is based on the fact that a functional respiratory chain is necessary for mtROS production. Therefore, we evaluated whether the modulation of electron transport chain activity by EtBr would reduce E2-induced DNA synthesis. As shown in Figure 2b , DNA synthesis significantly decreased by 60% in E2-treated mitochondrial transcription/replication-blocked cells when compared to MCF7 cells at 18 h. The chemical rhodamine 6G (R6G) was used as an alternative approach to evaluate the influence of mtROS on E2-induced DNA synthesis. Acute treatment with R6G has been shown to block effectively oxidative phosphorylation (Williams et al., 1999) . As shown in Figure 2b , E2-induced DNA synthesis was drastically reduced to the level of control at 48 h by R6G treatment. Rotenone also decreased E2-induced DNA synthesis to control level (Figure 2b ). Since cell growth and apoptosis are energy-dependent processes, we monitored whether ATP levels could account for the reduction of DNA synthesis observed in EtBr-treated cells as well as with rotenone treatment. As shown in Figure 2c , there was no significant difference in intracellular ATP levels in the EtBr-treated cells when compared to MCF7 after 18 h of E2 treatment. In addition, rotenone (1 mM) treatment did not show a significant difference in ATP levels when compared to E2 alone (Figure 2d) . Therefore, the reduction in E2-induced DNA synthesis is not due to a decrease in ATP levels.
The suppression of DNA synthesis by antioxidants further supports the hypothesis that E2-induced ROS modulates the process of cell proliferation. The impairment of E2-induced DNA synthesis by EtBr and R6G suggests that the electron transport chain is a source of E2-induced oxidants, which signal DNA replication. More specifically, respiratory complex I may be a source of the E2-induced ROS signal based on the effect of rotenone. Therefore, our Estrogen-induced mitochondrial ROS regulate G1/S transition Q Felty et al findings suggest that oxidant signaling from the mitochondria to the nucleus supports E2-induced DNA synthesis.
Mitochondrial blockers prevent E2-induced G 1 /S transition of G 0 -arrested cells
Recently, the regulation of G 1 to S-phase transition in fibroblast cells was reported to depend on the intracellular redox state (Menon et al., 2003) . Since our data suggested that DNA synthesis is controlled by E2-induced ROS, we further evaluated the fate of E2-treated cells within the cell cycle in the presence of various mitochondrial blockers. Cells were synchronized by serum starvation for 24 h and induced to re-enter the cell cycle by E2 (100 pg/ml) treatment with or without mitochondrial blockers. Fluorescence-activated cell sorting (FACS) analysis of DNA content was performed on cells stained with propidium iodide. FACS data are presented as representative histograms from three separate experiments in Figure 3 and results are summarized in Table 1 . We first examined the effect of E2 on MCF7 cells that were treated with the mitochondrial transcription/replication blocker EtBr. In E2-treated MCF7 cells, the percentage of DNA content in S phase was 18%, while this decreased to 6.8% in EtBrtreated MCF7 after 24 h (Table 1) . Treatment with the antibiotic chloramphenicol was used as an alternate approach to study the effect of blocking mitochondrial transcription/replication on E2-induced cell cycle progression. After 24 h exposure to E2, the percentage of DNA content in S phase was 16.6%, which decreased to 11.5% in the chloramphenicol-treated cells (Table 1) .
Our final approach consisted of acute treatments with blockers of mitochondrial function. MCF7 cells were pretreated for 2 h with specific blockers of respiratory complex I (rotenone) and complex III (antimycin A) prior to 24 h E2 treatment. Rotenone and antimycin A decreased the percentage of DNA content in S phase to 8.5 and 6.0%, respectively, when compared to 19.8% in the E2 treatment (Table 1) . A similar decrease in S phase DNA content of 10.5% was observed with R6G compared to 18.8% in the E2 treatment (Table 1) Interestingly, the ATP synthase blocker, oligomycin B, did not suppress G 1 to S-phase transition, instead DNA content was increased to 22.3%. The FACS data not only confirm the results shown by the BrdUrd assay but also show that impairment of mitochondrial function prevents E2-induced entry of MCF7 cells into the S phase by arresting them in the G 0 /G 1 phase.
Mitochondrial blockers reduce cell cycle gene expression
Gene expression was screened using the human cell cycle nonradioactive GEArray Q Series Kit (SuperArray Inc., Bethesda, MD, USA) to determine whether the arrest in G 0 /G 1 phase and the inhibition of DNA synthesis were due to changes at the level of gene expression. A representative graph containing all the cell cycle genes screened by the cDNA array at 24 h in R6G-and EtBrtreated cells is shown in Figure 4a . At 24 h, cell cycle genes for cyclins D3 and B2, PCNA, PRC1, p53, and bcl-2 were selected based on a twofold or more increase in expression. We investigated the effects of R6G in more detail because R6G is considered to be a more potent agent than EtBr with respect to disabling mitochondrial function. A 24 h R6G treatment prevented E2-induced expression of G 1 phase markers cyclins D3 and B2, S-phase marker PCNA, DNAdamage markers bcl-2 and p53, and M stage marker PRC1 (Figure 4b ). Reduction in gene expression by R6G treatment was further confirmed by RT-PCR. Except for p53, the expression of cyclins D3 and B2, PCNA, PRC1, and bcl-2 were all decreased by R6G treatment (Figure 4c) . Results from our 6 h cDNA array showed a significant change in cyclins involved in the G 1 to S-phase Figure 3 Mitochondrial blockers arrest E2-induced cell growth at G 1 phase of cell cycle. MCF7 were seeded in T-25 flasks grown 1 day in 10% FBS DMEM/F12, serum starved 1 day, and pretreated for 2 h with R6G (0.5 mg/ml), rotenone (25 ng/ml), antimycin A (25 ng/ml), and oligomycin B (25 pg/ml) followed by E2 (100 pg/ml) for 24 h. Chloramphenicol-(100 mg/ml) and EtBr-treated MCF7 cells were treated as previously described followed by 24 h E2 treatment. FACS data are presented as representative histograms from three separate experiments. Data were analysed by ModFitLt s V2.0 cell cycle kinetics Estrogen-induced mitochondrial ROS regulate G1/S transition Q Felty et al transition. The expression of cyclins D1, E1, and E2 were increased 2.8-, 3.6-, and 2.3-fold, respectively, when compared to control with E2 treatment (Figure 5a and b). Impairment of mitochondrial transcription/ replication by EtBr treatment decreased E2-induced expression of cyclins D1, E1, and E2 to 1.1-, 1.4-, and 2.3-fold, respectively (Figure 5a ). In the presence of the mitochondrial blocker R6G, E2 treatment resulted in a 0.5-, 0.3-, and 0.2-fold induction of cyclins D1, E1, and E2, respectively (Figure 5b ). In addition to the cyclins, gene expression of the mitochondrial protein bcl-2 was induced 10-fold in E2-treated cells, while it decreased to about 1.1-fold in EtBr-and R6G-treated MCF7 cells (Figure 5a and b) . Several studies have implicated cyclin D1 involvement in estrogen-dependent growth of both normal and malignant mammary epithelial cells. For instance, hormone-dependent growth of breast epithelium is impaired in cyclin D1-deficient mice (Sicinski et al., 1995) , and in MCF7 cells, cyclin D1 is a well-defined target of E2 action (Foster et al., 2001) . Since these studies suggest a direct regulation of cyclin D1 expression by E2 in the process of cell proliferation, we selected cyclin D1 to investigate the effect of E2-induced mtROS on the early G 1 phase of the cell cycle.
We first determined whether E2-induced cyclin D1 expression was modulated by oxidants. MCF7 cells were pretreated for 2 h with the antioxidants ebselen (20 mM) and NAC (10 mM) followed by a 3 h E2 treatment. As shown in Figure 5c , real-time PCR analysis showed a decrease in the level of cyclin D1 expression by both antioxidants when compared to E2 treatment alone. 
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Next, we evaluated whether the oxidant-dependent expression of cyclin D1 was a function of mtROS. As shown in Figure 5c , rotenone drastically reduced cyclin D1 expression. In addition, impairment of oxidative phosphorylation by R6G decreased the level of E2-induced cyclin D1 expression (Figure 5d ). Since the cyclin D1 promoter contains the regulatory elements TRE and CRE (Herber et al., 1994a) , we confirmed our real-time PCR data by investigating whether NAC and/or rotenone could modulate the binding of redoxsensitive transcription factors AP-1 and CREB by Electrophoretic mobility shift assay (EMSA). The oligonucleotide sequences for both regulatory elements TRE and CRE were obtained from the human cyclin D1 promoter region. As shown in Figure 5d , AP-1 transcriptional activity of cyclin D1 is significantly reduced by NAC (10 mM) treatment. We also showed a dramatic decrease in CREB transcriptional ) were grown 1 day, serum starved 2 days, and prior to E2 treatment. Cells were pretreated with rotenone (10 mg/ml) for 15 min, rinsed with PBS, followed by E2 treatment for another 3 h. Pretreatment with ebselen (20 mM) and NAC (10 mM) was followed by 3 h E2 treatment. (d) Pretreatment of R6G (0.5 mg/ml) for 1 h. Cyclin D1 expression after 3 h E2 treatment. (e) EMSA with cyclin D1-specific AP-1 consensus sequence from promoter region. MCF7 cells were pretreated with NAC for 2 h prior to 3 h E2 treatment. (f) EMSA with cyclin D1-specific CREB consensus sequence from promoter region. MCF7 cells were pretreated with rotenone for 15 min, rinsed with PBS, and then treated with E2 another 3 h. The blots shown are representative of three separate experiments Estrogen-induced mitochondrial ROS regulate G1/S transition Q Felty et al activity of cyclin D1 by rotenone (Figure 5e ). Together, these findings suggest that the E2-induced transcription of cyclin D1 depends on oxidants of mitochondrial origin.
Discussion
The data presented here lead to three major novel findings: (i) ROS play a role in G 1 to S progression of estrogen-stimulated breast epithelial cancer cells, (ii) modulation of mitochondrial function, mitochondrial protein synthesis, or mitochondrial transcription/replication block estrogen-induced cell cycle progression from G 1 to S without influencing the level of ATP, and (iii) estrogen-induced early G 1 progression is partly attributed to nongenomic ER signaling. In our model, cells were blocked at the G 1 /S boundary by serum starvation, and then pushed into S phase by the addition of estrogen. We demonstrated that the antioxidants ebselen and NAC block E2-induced DNA synthesis or S-phase progression. Like several growth factors known to stimulate ROS, which are believed to participate in cell growth, our findings suggest that this underlying mechanism of cell growth is shared with estrogen. Although the source and identity of the oxidant(s) was not investigated in this study, the source of ROS (hydrogen peroxide) is mostly mitochondrial (Q Felty et al., unpublished) , which is known to be a major source of oxidants in epithelial cells. The redox cycling of catechol estrogens could also be another source of ROS. We were the first to show that estrogens are hydroxylated to catechol estrogens, and catechol estrogens participate as a substrate in the P450 catalysed redox reactions (Roy and Liehr, 1988; Liehr and Roy, 1990) . However, it is unlikely that redox cycling of catechol estrogens occur immediately after E2 exposure, as E2 would have to be hydroxylated and oxidized to a reactive intermediate in the endoplasmic reticulum prior to its transport to the mitochondria and cytosol. Although this type of redox reaction may play a role in the generation of ROS, it appears to be a latter event.
In our studies of E2-induced ROS generation in MCF7 and other cells, we were not able to find any hydroxylated estrogen metabolites or their adducts immediately after the addition of E2. Moreover, the cell-impermeable estrogen conjugate, E2-BSA, produced a rapid (5 min) induction of ROS. Since E2-BSA cannot enter the cell to be metabolized, this is further evidence that the ROS is not from catechol estrogen redox cycling. Our results show that blockers of mitochondrial transcription/replication significantly reduced E2-induced DNA synthesis and blocked cells from progression into S phase. Acute blockers of mitochondrial function (rotenone, antimycin A, and R6G) also resulted in a reduction of cell proliferation. This block of G 1 to S phase progression was also shown by the decreased gene expression of cyclins D1, E1, and E2. Therefore, these findings implicate a role for mitochondria in E2-stimulated G 1 to S-phase progression. Interestingly, neither the antioxidants (ebselen and NAC) or mitochondrial blockers (rotenone, EtBr, chloramphenicol) are reported to bind the ER, which supports the idea that these effects on early G 1 -phase progression occur independent of a genomic ER signaling pathway.
Several lines of indirect evidence support a role for mitochondrial oxidants in estrogen-induced cell proliferation. Dominant-negative inhibition of thioredoxin reductase 2 (TrxR2) causes an increase in hydrogen peroxide accumulation, which activates cell proliferation (Kim et al., 2003) and increased expression of cell cycle genes involved in the G 1 and S phases of the cell cycle. In vitro E2 treatment (10-100 nM) of primary human endometrial stromal cells results in an increase in Trx protein and mRNA, which implicates Trx in cell growth and differentiation of estrogen-responsive tissue (Maruyama et al., 1999) . Whether estrogen can specifically increase the expression or activity of Trx2 and/or TrxR2 is not known, but these findings suggest that estrogen may modulate signal transduction of mitochondrialderived ROS via the thioredoxin system. We have shown that E2 stimulates mtROS at the level of the plasma membrane most likely through the ligation of integrins (Q Felty et al., unpublished data). Integrin clustering in the absence of cell spreading was sufficient to induce expression of early genes (jun B and ras) involved in the G 0 /G 1 phase and were able to trigger G 1 /S transition through modulating cyclin D1 expression (Honore et al., 2003) . Integrins, through ROS, control the expression of these cell cycle genes, and it is now obvious that cell adhesion and integrin ligation are obligatory processes for the regulation of cdks and cyclins. The expression of early G 1 genes, cmyc, c-fos, c-jun, and cyclin D1 are regulated by ROS (Janssen et al., 1997; Simon et al., 1998; Galli et al., 2003) . We have shown that E2-induced ROS activate transcription factors NRF-1, AP-1, and CREB, which are known to be involved in the transcription of cell cycle genes such as cyclin D1 (Q Felty et al., unpublished) . In addition to E2-mediated ER signaling, our findings suggest that E2-induced mtROS also activates transcription factors AP-1, NRF-1, and CREB, which transcribe cell cycle genes such as cyclin D1, in turn, leading to G 1 /S-phase progression of estrogen-dependent cells.
The contribution of E2 in the promotion of uterine, breast, ovarian, and cervix tumors is widely accepted. ER-mediated signaling pathways are considered to support the growth of preneoplastic and malignant breast cells. However, data obtained from various laboratories show that the receptor binding activity of estrogen does not correlate with its influence on in vitro and in vivo growth of some cells (Roy and Cai, 2002) . Recently, we identified that E2 stimulated the growth of HEK293 cells in an ER-independent manner given that this cell line is reported not to express the ER ( KP Singh et al., unpublished) . The introduction of the Wnt-1 transgene into ERa knockout mice resulted in the development of spontaneous mammary tumors in 100% of adult females, indicating that mammary tumors develop despite a lack of functional ER (Bocchinfuso et al., 1999) . The prevention of breast cancer cell growth by SERMS such as tamoxifen and antiestrogens such as ICI 182 780 does not mean that these compounds inhibit cancer only through the competitive binding of ERs. Since these compounds can block the metabolism/redox cycling of E2 as well as act like free radical scavengers (Arteaga et al., 2003) , it is possible that the therapeutic effect of these chemicals in part occurs through nongenomic ER signaling pathways. Estrogen-induced tumor formation is decreased in animals exposed to inhibitors of estrogen metabolism or to hormonally potent estrogens with decreased metabolic conversion to catechol metabolites compared to E2 (Roy and Cai, 2002) . Additionally, we and others have shown that antioxidants (Roy and Cai, 2002) and antiinflammatory agents (Harris et al., 2003) are effective in reducing E2-induced kidney tumor incidence in Syrian hamsters as well as reduce the growth of breast cancer cells, respectively. These findings support our present findings that in addition to ER-mediated genomic signaling pathways, nongenomic pathway(s) are involved in support of estrogen-dependent growth of preneoplastic and neoplastic breast cells.
In summary, the major novel finding that emerged from this study is that estrogen regulates the early G 1 stage of the cell cycle through mtROS, which has major implications in understanding the role of estrogen in initiation and progression of breast cancer cells. Findings of this study not only provide a new paradigm in understanding the mechanism of estrogen-induced proliferation and cell transformation but also provide important information for the design of new antioxidant-based drugs or new antioxidant gene therapy targeted for the prevention and treatment of estrogendependent breast cancer.
Materials and methods

Cell culture
MCF7 cells (ATCC) were propagated in DMEM/F12 medium without phenol red supplemented with 10% FBS and 1 Â antibiotic-antimycotic. Serum deprivation was used to synchronize the majority of MCF7 cells in the G 0 /G 1 phase of the cell cycle. After serum deprivation, cells were treated in fresh medium with mitochondrial inhibitors and a physiologically relevant dose of E2 or an equal volume of vehicle control (DMSO).
Mitochondrial blockers
Mitochondrial transcription/replication was impaired in MCF7 cells by culturing cells in routine growth medium supplemented with a low dose of EtBr (50 ng/ml), pyruvate (1 mM), and uridine (50 mg/ml) for 20 days (King and Attardi, 1996; Delsite et al., 2002) . An alternative approach to blocking mitochondrial transcription/replication was to block mitochondrial protein synthesis by prolonged treatment with chloramphenicol (100 mg/ml) or doxycycline (2.5 mg/ml) for 3 days prior to experiments (Maddaiah et al., 1973; van den et al., 1986; Pan-Zhou et al., 2000) . Acute (1-2 h) exposure with blockers of oxidative phosphorylation was also given prior to E2 treatment. These blockers include the chemicals R6G, rotenone, antimycin A, and oligomycin B. R6G blocks oxidative phosphorylation and is considered to be the most potent agent to impair mitochondrial transcription/replication in cells (Williams et al., 1999) . Rotenone and antimycin A block electron transport in mitochondrial respiratory complexes I and III, respectively, while oligomycin B binds to ATP synthase F0 subunit and blocks the flow of protons through the channel (Szewczyk and Wojtczak, 2002) .
Cell growth
MCF7 cells were seeded at 5 Â 10 5 cells per T-25 flask in triplicate and grown 1 day (50% confluency) in 10% FBS DMEM/F12 followed by serum deprivation for 2 days. Next, cells were treated with various mitochondrial blockers, antioxidants, and E2 as described in the figure legends for 72 h. Cell counts were determined by microscopic examination on a hemacytometer using trypan blue exclusion technique. Alternatively, measurement of cell growth was confirmed by SRB assay as described in the figures (Skehan et al., 1990) . Dye intensity was measured at 560 nm (reference l at 700 nm) on a Tecan Genios plate reader.
BrdUrd cell proliferation assay MCF7 cells were grown (2500 cells/well) in 96-well plates until 50% confluent in 10% FBS DMEM/F12, and serum starved for 2 days followed by treatments as described in the figures for 24-48 h. A colorimetric BrdUrd cell proliferation assay was performed according to the manufacturer's instructions (Roche). Absorbance of the samples was measured in a Tecan Genios plate reader at 450 nm (reference l at 700 nm).
ATP assay
In opaque-walled 96-well plates, cells (2500 cells/well) were seeded and cultured as previously described in the cell proliferation assay. After 24 h E2 treatment, the CellTiterGlot Luminescent Cell Viability Assay (Promega) was used to measure the amount of ATP present in cells. Cells were prepared according to the manufacturer's instructions. Luminescence was measured with a Tecan Genios plate reader.
Flow cytometry
For flow cytometry, cells were harvested by trypsinization and fixed in 70% ethanol. After permeabilization, cells were washed in PBS and resuspended at 10 6 cells/ml. Cells were incubated with RNase (Roche) for 30 min and stained with propidium iodide (10 mg/ml). Samples (cells 5 Â 10 5 ) were analysed by the UAB Core Facility for Flow Cytometry with a Becton Dickinson FACStar cytometer/sorter. Data were analysed by ModFitLt s V2.0.
Cell cycle cDNA array
Gene expression was measured using the Nonradioactive GEArray Q Series Kit (SuperArray Inc., Bethesda MD, USA) for human cell cycle genes. MCF7 cells and EtBrtreated MCF7 cells were treated with E2 (100 pg/ml) and R6G (0.5 mg/ml) for 6 and 24 h. Total RNA was isolated from cells using TRIzol s Reagent (Invitrogen). Total RNA was used as the template for cDNA probe synthesis according to the manufacturer's instructions. The GEArray membrane was hybridized with denatured cDNA probe of the samples overnight and gene expression was detected by chemiluminescent reaction exposed to X-ray film. Signals were quantitated by scanning the film with an HP ScanJet, and the intensity value of the spots was obtained using the image analysis program Scanalyze (Michael Eisen, Stanford). After obtaining intensity values, each gene was normalized to the housekeeping gene ribosomal protein L13a (RPL13A) using the GEArrayAnalyzer program (SuperArray, Inc.).
Post-cDNA array analysis cDNA was synthesized by using standard RT reaction followed by PCR amplification as described previously (DuMond Jr et al., 2001a, b) on the following cell cycle genes: cyclin D3 (Uchimaru et al., 1997) , cyclin B2 (Krause et al., 2000) , PCNA (Ramachandran et al., 2000) , PRC1 (Chang et al., 2000) , bcl-2 (Wang and Phang, 1995), p53 (Formby and Wiley, 1999) , and b-actin (Wei et al., 1997) . Primers were synthesized by the UAB Comprehensive Cancer Center Oligo Core Facility (Table 2 ). The PCR amplification was performed in a Perkin-Elmer Cetus DNA Thermal Cycler programmed as described previously. PCR samples were analysed by electrophoresis on 1.5% agarose gels.
Real-time PCR analysis
Single-step RT-PCR amplification was performed with the LightCycler RNA Amplification Kit SYBR Green I according the manufacturer's protocol (Roche). Total RNA (500 ng) was amplified in an MJ Research DNA Engine Opticon s 2 programmed for reverse transcription at 551C for 15 min, denaturation at 951C for 1 min, followed by 40 cycles of 30 s denaturation at 951C, 30 s annealing at 551C, and 30 s extension at 721C. The primer sequences used for cyclin D1 were 5 0 -AACTACCTGGACCGCTTCCT-3 0 (sense) and 5 0 -CCACTTGAG CTTGTTCACCA-3 0 (antisense) (Paruthiyil et al., 2004) , and 18S rRNA primers were purchased from Ambion.
Electrophoretic mobility shift assay
EMSA was performed with DIG-11-ddUTP 3 0 -end-labeled probes. The AP-1 consensus sequence (5 0 -AAAAAAAAT GAGTCAGAATGGAGATCAC-3 0 (sense) and 3 0 -TTTTAC TCAGTCTTACCTCTAGTGACAA-5 0 (antisense)) and the CRE consensus sequence (5 0 -TAACAACAGTAACGTCA CACGGACTACA-3 0 (sense) and 3 0 -TGTCATTGCAGTG TGCCTGATGTCCCCT-5 0 (antisense)) were taken from the human cyclin D1 promoter region (Herber et al., 1994b) . Probe labeling and binding reactions were performed following the protocols provided by the DIG Gel Shift Kit manufacturer (Roche). Samples were electrophoresed on a 6% native polyacrylamide gel and transferred to a nylon membrane by electroblotting. Binding was detected by chemiluminescent detection as described in the DIG Gel Shift Kit protocol (Roche).
Statistical analysis
Results are expressed as means7s.d. Differences between means were evaluated by two-tailed Student's t-test. ANOVA was used to determine differences between groups. 
